cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Anak Agung Gde Putra Wiraguna
Contact Email
editor.balidv@gmail.com
Phone
+6282339990824
Journal Mail Official
editor.balidv@gmail.com
Editorial Address
Dermatology and Venereology Department, Medical Faculty, Universitas Udayana/Prof. dr. I G. N. G. Ngoerah General Hospital, 3rd Floor (Jl. Diponegoro, Dauh Puri Klod, Kecamatan Denpasar Barat, Kota Denpasar, Bali 80113)
Location
Kota denpasar,
Bali
INDONESIA
Bali Dermatology Venereology and Aesthetic Journal
Published by Universitas Udayana
ISSN : 30467985     EISSN : 30467993     DOI : https://doi.org/10.51559/balidervenaesthj.v6i1.33
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Bali Dermatology Venereology and Aesthetic Journal is an open access; peer-reviewed journal aiming to communicate high-quality research articles, reviews, and general articles in the Dermatology, Venereology and Aesthetic field. The Journal aims to bridge and integrate the intellectual, methodological, and substantive diversity of Dermatology, Venereology and Aesthetic and to encourage a vigorous dialogue between researcher, medical scholars and practitioners. The scope of this journal includes: General dermatology Venereology Cosmetic dermatology/aesthetic Pediatric dermatology Allergy and immunology Skin and tumor surgery Tropical dermatology Genodermatosis (hereditary skin disease) Travel dermatology Traditional, Complementary, and Integrative medicine in dermatology Diagnostic method and artificial intelligence in dermatology
Arjuna Subject : Kedokteran - Dematologi
Articles 82 Documents
 5   6   7   8   9 
Genetic susceptibility to dermatophyte infections: a review Luh Gede Melia Puspita Sari Puspita Sari; I Gusti Ayu Agung Dwi Karmila; Putu Ayu Yunita Primasari
Bali Dermatology Venereology and Aesthetic Journal BDVAJ - Volume 9, Issue 1 (2026)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/balidervenaesthj.v9i1.127

Abstract

Dermatophytes infect people of all ages, races, genders, and socioeconomic statuses. However, some groups of individuals tend to be more susceptible. Several risk factors have been described, particularly in immunocompromised individuals and patients with severe illnesses.  Unfortunately, this still does not explain why only some immunocompetent individuals experience infections. Some studies have concluded that genetic susceptibility is associated with defects in Toll-like receptors involved in the inflammatory response and pathogen clearance mechanisms, C-type lectin receptors, nucleotide-binding and oligomerization domain (NOD)-like receptors, and defects in soluble pattern recognition receptors, which can lead to impaired phagocytosis and pathogen elimination by neutrophils. The purpose of this article is to highlight how the human body reacts to fungal exposure and a number of genetic changes that may be the cause of fungal infections, even in immunocompetent people.
Efficacy and Safety of Terbinafine Compared with Other Antifungal Agents in Dermatophytosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials Ida Ayu Uttari Priyadarshini; Putu Tiara Mas Pracinti Ariesta Putri; Putu K. Helsayani
Bali Dermatology Venereology and Aesthetic Journal BDVAJ - Volume 9, Issue 1 (2026)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/balidervenaesthj.v9i1.133

Abstract

Background: Dermatophytosis is a frequent superficial fungal infection that causes significant morbidity and is increasingly associated with treatment failure. Terbinafine is frequently used as a first-line therapy; however, its relative efficacy compared with other antifungal agents remains inconsistent. This study aimed to assess the effectiveness and safety of Terbinafine compared to other antifungal agents in patients with dermatophytosis. Methods: A systematic review and meta-analysis of the past 20 years was conducted following PRISMA 2020 guidelines. The databases used were PubMed, the Cochrane Library, and ScienceDirect. The outcomes assessed included overall cure, mycological cure, clinical cure, treatment failure, and adverse events. Random-effects models calculated risk ratios (RRs) and 95% confidence intervals (CIs). Results: Thirteen RCTs were analyzed. No notable differences were found between Terbinafine and other antifungal agents in overall cure (RR: 0.87; 95% CI: 0.74–1.02), mycological cure (RR: 1.11; 95% CI: 0.89–1.38), or clinical cure (RR: 1.06; 95% CI: 0.96–1.16). However, Terbinafine was associated with a higher risk of treatment failure (RR: 6.22; 95% CI: 1.50–25.80). Subgroup analyses indicated Terbinafine was less effective for tinea corporis and tinea cruris, but more effective for tinea capitis. There were no significant differences in adverse events between the groups. Conclusion: Terbinafine demonstrated efficacy comparable to that of other antifungal agents, but it may increase the risk of treatment failure under certain conditions. Its effectiveness appears to be context-dependent and influenced by the type of dermatophytosis and the causative pathogen.

Page 9 of 9 | Total Record : 82

 5   6   7   8   9 

Filter by Year

2018 2026


Reset
Filter By Issues
All Issue BDVAJ - Volume 9, Issue 1 (2026) BDVAJ - Volume 8, Issue 2 (2025) BDVAJ - Volume 8, Issue 1 (2025) BDVAJ - Volume 7, Issue 2 (July 2024) BDVAJ - Volume 7, Issue 1 (January 2024) BDVAJ - Volume 6, Issue 2 (December 2023) BDVAJ - Volume 6, Issue 1 (June 2023) BDVJ - Vol. 5 No. 2 (December 2022) BDVJ - Vol. 5 No. 1 (June 2022) BDVJ - Vol. 4 No. 2 (December 2021) BDVJ - Vol. 4 No. 1 (June 2021) BDVJ - Vol. 3 No. 2 (December 2020) BDVJ - Vol. 3 No. 1 (June 2020) BDVJ - Vol. 2 No. 2 (December 2019) BDVJ - Vol. 2 No. 1 (June 2019) BDVJ - Vol. 1 No. 2 (December 2018) BDVJ - Vol. 1 No. 1 (June 2018) More Issue